A carregar...
Ligand-based receptor tyrosine kinase partial agonists: New paradigm for cancer drug discovery?
INTRODUCTION: Receptor tyrosine kinases (RTKs) are validated targets for oncology drug discovery and several RTK antagonists have been approved for the treatment of human malignancies. Nonetheless, the discovery and development of RTK antagonists has lagged behind the discovery and development of ag...
Na minha lista:
| Autor principal: | |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2011
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3083243/ https://ncbi.nlm.nih.gov/pubmed/21532939 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1517/17460441.2011.547468 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|